scholarly journals Experimental studies for the personalized application of boron neutron capture therapy to the treatment of cutaneous melanoma

2021 ◽  
Vol 0 ◽  
pp. 0-0
Author(s):  
Marina Carpano ◽  
Gustavo Santa Cruz ◽  
Carla Rodriguez ◽  
Susana Nievas ◽  
Maria Silvina Olivera ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Cutaneous Melanoma ◽  
Neutron Capture ◽  
Experimental Studies ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

scholarly journals Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)

2020 ◽  
Vol 61 (6) ◽  
pp. 945-951
Author(s):  
Junichi Hiratsuka ◽  
Nobuhiko Kamitani ◽  
Ryo Tanaka ◽  
Ryoji Tokiya ◽  
Eisaku Yoden ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Cutaneous Melanoma ◽  
Neutron Capture ◽  
Early Stage ◽  
Regional Lymph Node ◽  
Skin Dose ◽  
Neutron Capture Therapy ◽  
Long Term Outcome ◽  
Boron Neutron Capture

ABSTRACT Our aim was to assess the long-term clinical outcome of boron neutron capture therapy (BNCT) using 10B-para-boronophenylalanine (BPA) as the boron delivery agent for cutaneous melanoma. Eight patients (eight lesions) were treated between October 2003 and April 2014. Their ages ranged from 48 to 86 years at the time of treatment. All of the targets were primary lesions and they were located on the sole or face. No patient had evidence of regional lymph node involvement, distant metastases or an active secondary cancer. The clinical stage was cT1-2N0M0 and performance scores were <2. BNCT was carried out at the Kyoto University Research Reactor (KUR). The patients were irradiated with an epithermal neutron beam between the curative tumor dose and the tolerable skin dose. Eight patients were evaluated and six showed a complete response (CR), while two patients had a partial response (PR). Of the two patients with a PR, one has remained a PR with brown spots persisting for 7.5 years following BNCT. The tumor in the other patient recurred after 6 years at the site of persisting brown macula. The overall control rate (CR + PR without recurrence) for the cohort was 88% (7/8). There have never been any adverse events >Grade 2 for the long follow-up period. Our results suggest that BNCT may be a promising treatment modality in the management of early stage cutaneous melanoma when wide local excision is not feasible.

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Nucleophilic radiosynthesis of boron neutron capture therapy-oriented PET probe [18F]FBPA using aryldiboron precursors

2021 ◽  
Author(s):  
Jing He ◽  
Heng Yan ◽  
Yanrong Du ◽  
Yan Ji ◽  
Fei Cai ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

A reliable copper-mediated nucleophilic radiosynthesis of the BNCT-oriented PET probe [18F]FBPA was developed using novel aryldiboron precursors.

scholarly journals Optimized beam shaping assembly for a 2.1-MeV proton-accelerator-based neutron source for boron neutron capture therapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Pablo Torres-Sánchez ◽  
Ignacio Porras ◽  
Nataliya Ramos-Chernenko ◽  
Fernando Arias de Saavedra ◽  
Javier Praena
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Beam Shaping ◽  
Proton Accelerator ◽  
Neutron Capture Therapy ◽  
Beam Shape ◽  
New Era ◽  
Boron Neutron Capture ◽  
Optimal Beam ◽  
Beam Shaping Assembly

AbstractBoron Neutron Capture Therapy (BNCT) is facing a new era where different projects based on accelerators instead of reactors are under development. The new facilities can be placed at hospitals and will increase the number of clinical trials. The therapeutic effect of BNCT can be improved if a optimized epithermal neutron spectrum is obtained, for which the beam shape assembly is a key ingredient. In this paper we propose an optimal beam shaping assembly suited for an affordable low energy accelerator. The beam obtained with the device proposed accomplishes all the IAEA recommendations for proton energies between 2.0 and 2.1 MeV. In addition, there is an overall improvement of the figures of merit with respect to BNCT facilities and previous proposals of new accelerator-based facilities.

Sign in / Sign up

Export Citation Format

Share Document